Who are Rebif® (clone 484-39)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rebif New Formulation + ibuprofen PRN, Rebif New Formulation + prophylactic Ibuprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rebif-clone-484-39.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rebif® (clone 484-39) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rebif® (clone 484-39) (Rebif® (clone 484-39)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon beta-1a. Area: Immunology / Neurology.

marketed Interferon beta-1a Type I interferon receptor (IFNAR) Immunology / Neurology Biologic Live · refreshed every 30 min

Target snapshot

Rebif® (clone 484-39) (Rebif® (clone 484-39)) — Merck KGaA, Darmstadt, Germany. Rebif is an interferon beta-1a that activates interferon receptors on immune cells to modulate immune response and reduce inflammation in the central nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rebif® (clone 484-39) TARGET	Rebif® (clone 484-39)	Merck KGaA, Darmstadt, Germany	marketed	Interferon beta-1a	Type I interferon receptor (IFNAR)
Rebif New Formulation + ibuprofen PRN	Rebif New Formulation + ibuprofen PRN	Merck KGaA, Darmstadt, Germany	phase 3	Interferon beta-1a	Interferon-beta receptor (IFNAR)
Rebif New Formulation + prophylactic Ibuprofen	Rebif New Formulation + prophylactic Ibuprofen	Merck KGaA, Darmstadt, Germany	phase 3	Interferon beta-1a	Interferon-beta receptor (IFNBR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon beta-1a class)

Merck KGaA, Darmstadt, Germany · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rebif® (clone 484-39) — Competitive Intelligence Brief. https://druglandscape.com/ci/rebif-clone-484-39. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing